T3 Companies’s VYNE Therapeutics VYNE Stock Holding History

T3 Companies’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$565K	Hold	945,000	–	–	0.74%	27
2025 Q4	$548K	Buy	+945,000	New	+$379K	0.68%	31

Other funds holding VYNE

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

KCA

KVP Capital Advisors San Francisco, California $134M AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

T3 Companies's VYNE Position: Q1 2026 in Review

T3 Companies held its VYNE Therapeutics (VYNE) position steady in Q1 2026 at 945,000 shares worth $565K. The position accounts for 0.74% of the portfolio, ranked #27.

T3 Companies first reported a position in VYNE in Q4 2025 and has held it in 2 quarters since. 45 funds tracked by Wall St. Rank hold VYNE as of Q1 2026.

T3 Companies held 945,000 shares of VYNE Therapeutics worth $565K as of Q1 2026.
T3 Companies left its VYNE Therapeutics share count unchanged in Q1 2026.
VYNE Therapeutics made up 0.74% of T3 Companies's portfolio in Q1 2026, its #27 holding.
T3 Companies first reported a position in VYNE Therapeutics in Q4 2025 and has held it in 2 quarters since.
45 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2026.

Based on T3 Companies's 13F filing for Q1 2026, filed 7 May 2026.